Advantage Alpha Capital Partners LP Has $222,000 Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Advantage Alpha Capital Partners LP lessened its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 49.3% in the 4th quarter, HoldingsChannel.com reports. The fund owned 5,742 shares of the company’s stock after selling 5,594 shares during the period. Advantage Alpha Capital Partners LP’s holdings in Protagonist Therapeutics were worth $222,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the stock. Franklin Resources Inc. lifted its holdings in Protagonist Therapeutics by 127.2% in the 3rd quarter. Franklin Resources Inc. now owns 81,591 shares of the company’s stock worth $3,782,000 after purchasing an additional 45,674 shares during the last quarter. Swedbank AB bought a new position in shares of Protagonist Therapeutics in the third quarter valued at approximately $2,250,000. Charles Schwab Investment Management Inc. raised its position in shares of Protagonist Therapeutics by 7.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 565,503 shares of the company’s stock valued at $25,448,000 after purchasing an additional 39,850 shares during the period. Principal Financial Group Inc. lifted its stake in shares of Protagonist Therapeutics by 3,099.4% in the third quarter. Principal Financial Group Inc. now owns 320,832 shares of the company’s stock worth $14,437,000 after buying an additional 310,804 shares during the last quarter. Finally, Intech Investment Management LLC bought a new stake in shares of Protagonist Therapeutics during the 3rd quarter worth $861,000. Institutional investors own 98.63% of the company’s stock.

Insider Buying and Selling at Protagonist Therapeutics

In other Protagonist Therapeutics news, CFO Asif Ali sold 24,903 shares of Protagonist Therapeutics stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $58.73, for a total value of $1,462,553.19. Following the completion of the transaction, the chief financial officer now owns 62,821 shares in the company, valued at approximately $3,689,477.33. The trade was a 28.39 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director William D. Waddill sold 4,000 shares of the company’s stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $54.25, for a total transaction of $217,000.00. Following the transaction, the director now owns 13,130 shares in the company, valued at approximately $712,302.50. This trade represents a 23.35 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 64,776 shares of company stock worth $3,585,010 over the last ninety days. Corporate insiders own 5.40% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on PTGX shares. BMO Capital Markets lifted their price objective on Protagonist Therapeutics from $62.00 to $72.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 11th. Truist Financial lifted their price target on Protagonist Therapeutics from $60.00 to $76.00 and gave the stock a “buy” rating in a research report on Tuesday, March 11th. HC Wainwright reissued a “buy” rating and issued a $54.00 price objective on shares of Protagonist Therapeutics in a research report on Monday, March 10th. The Goldman Sachs Group dropped their target price on shares of Protagonist Therapeutics from $43.00 to $38.00 and set a “neutral” rating on the stock in a research report on Monday, February 24th. Finally, StockNews.com downgraded shares of Protagonist Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, December 10th. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $62.56.

Protagonist Therapeutics Price Performance

Protagonist Therapeutics stock opened at $52.53 on Tuesday. The business has a 50 day simple moving average of $41.52 and a 200 day simple moving average of $42.70. The company has a market capitalization of $3.22 billion, a PE ratio of 19.75 and a beta of 2.34. Protagonist Therapeutics, Inc. has a one year low of $24.22 and a one year high of $60.60.

Protagonist Therapeutics (NASDAQ:PTGX) last issued its quarterly earnings data on Friday, February 21st. The company reported $1.98 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.09) by $2.07. Protagonist Therapeutics had a return on equity of 34.68% and a net margin of 52.76%. The company had revenue of $170.64 million during the quarter, compared to analysts’ expectations of $56.65 million. Equities analysts anticipate that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current fiscal year.

Protagonist Therapeutics Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.